Drug-Resistant Tuberculosis Treatment Market Segmented By Drug Class such as Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Cycloserine, Delamanid, Ethambutol, Ethionamide and Prothionamide, Fluoroquinolones,Azithromycin, Clarithromycin, p-Aminosalicylic Acid Pyrazinamide used for Diseases like Multidrug-Resistant TB (MDR TB), Extensively Drug-resistant TB (XDR TB) with First-Line Anti-TB Drugs and Second-Line Anti-TB Drugs Treatment Type
Report ID: PMRREP32634
Report Type: Ongoing
Format: PPT*, PDF, EXCEL
Industry: Healthcare
According to the latest research by Persistence Market Research, the Drug-Resistant Tuberculosis Treatment market is set to witness a growth of 5% during 2021-2031. Demand for Drug-Resistant Tuberculosis Treatment expects to witness steady recovery in the short-term, with an optimistic growth outlook in the long run. The growing advancement for the Drug-Resistant Tuberculosis Treatment market industry will offer lucrative opportunities in near future.
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report Sample
The WHO has described the global effects of multidrug-resistant tuberculosis (MDR TB) as a “public health crisis”. In 2013, an estimated 480,000 new cases and 210,000 deaths were caused by MDR TB which is defined by resistance to isoniazid and rifampin, the 2 most effective anti-TB drugs.
In addition, approximately 9% of MDR TB cases are believed to be extensively drug-resistant (XDR TB), which implies additional resistance to any fluoroquinolone and at least 1 injectable second-line drug. Treatment of MDR and XDR TB requires prolonged therapy with toxic, poorly tolerated medications, and for patients in developing countries, access to active drugs may be limited.
Drug-resistant TB is the largest single source of antimicrobial resistance in the world. According to WHO, approximately half a million people worldwide are diagnosed with multi-drug-resistant TB each year, and about 8.5% of those people have XDR TB.
Common TB treatments don’t work on XDR TB, so people with this extreme form of the disease need to take a combination of around eight drugs for more than a year. This growing number of drug-resistant tuberculosis will act as a driver for drug-resistant tuberculosis treatment market growth in the forecasted period.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionThere has been continuous research going on in the drug-resistant tuberculosis treatment field. FDA is actively involved in the approval of the related drugs. For instance, in Aug 2019, FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis. This continuous R&D will attract the market in the forecasted period.
North America held the majority of the revenue share of the global market in 2020. There has been a significant increase in the number of cases of MDR-TB in the United States. Although cases of MDR-TB have been reported from many areas of the country, the majority of the cases are concentrated in large urban areas.
MDR-TB is difficult and expensive to treat. CDC has developed a National Action Plan to Combat Multidrug-Resistant Tuberculosis. The U.S. has large support from government and insurance providers to facilitate the healthcare system. As the cell therapy treatment are expensive the favorable healthcare system of the region will promote the growth of the market in the forecasted period. Besides being a developed nation clinical trials are going on in the region facilitating the adoption of cell therapy.
Asia is the second-largest market for drug-resistant tuberculosis treatment. According to WHO, it is estimated that 171,000 Rifampicin-resistant (RR) and multi-drug-resistant TB (MDR-TB) cases accounting for more than 35% of global burden appeared in the region in 2019, of which around 70,000 were started on second-line treatment in the same year.
Six out of the 30 high TB (and MDR-TB) burden countries are in the region are Bangladesh, the Democratic People’s Republic of Korea, India, Indonesia, Myanmar, and Thailand. Central Asia accounts for 85% of the tuberculosis incidence and more than 90% of drug-resistant tuberculosis cases emerging in the region. This huge prevalence of MDR and XDR in the region will give rise to a drug-resistant tuberculosis treatment market in the forecasted period.
Some of the key players of Drug-Resistant Tuberculosis Treatment include
Companies offering Drug-Resistant Tuberculosis Treatment are involved in existing product upgrades, new product launches, mergers and acquisitions, and regional expansion to enhance their market position.
By Drug Class
By Disease Type
By Treatment Type
By Distribution channel
By Region
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
For report customisation and delivery information contact our sales representative.
